Gabather AB (publ) (GABA) - Total Assets
Based on the latest financial reports, Gabather AB (publ) (GABA) holds total assets worth Skr7.01 Million SEK (≈ $754.93K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Gabather AB (publ) to assess the company's total reinvestment commitment from operating cash flow.
Gabather AB (publ) - Total Assets Trend (2014–2025)
This chart illustrates how Gabather AB (publ)'s total assets have evolved over time, based on quarterly financial data. Check GABA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Gabather AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Gabather AB (publ)'s total assets of Skr7.01 Million consist of 98.7% current assets and 1.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.1% |
| Accounts Receivable | Skr637.00K | 16.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Gabather AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gabather AB (publ) (GABA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gabather AB (publ)'s current assets represent 98.7% of total assets in 2025, an increase from 93.0% in 2014.
- Cash Position: Cash and equivalents constituted 82.1% of total assets in 2025, down from 87.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 82.1% of total assets.
Gabather AB (publ) Competitors by Total Assets
Key competitors of Gabather AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Gabather AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.06 | 8.07 |
| Quick Ratio | 1.66 | 1.06 | 8.33 |
| Cash Ratio | 0.00 | 0.92 | 7.81 |
| Working Capital | Skr2.77 Million | Skr326.00K | Skr20.23 Million |
Gabather AB (publ) - Advanced Valuation Insights
This section examines the relationship between Gabather AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.90 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | 108.9% |
| Total Assets | Skr3.83 Million |
| Market Capitalization | $2.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gabather AB (publ)'s assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gabather AB (publ)'s assets grew by 108.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gabather AB (publ) (2014–2025)
The table below shows the annual total assets of Gabather AB (publ) from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr3.83 Million ≈ $412.17K |
+108.95% |
| 2024-12-31 | Skr1.83 Million ≈ $197.26K |
-75.11% |
| 2023-12-31 | Skr7.36 Million ≈ $792.48K |
+9.06% |
| 2022-12-31 | Skr6.75 Million ≈ $726.62K |
-56.13% |
| 2021-12-31 | Skr15.39 Million ≈ $1.66 Million |
-52.14% |
| 2020-12-31 | Skr32.16 Million ≈ $3.46 Million |
-30.19% |
| 2019-12-31 | Skr46.07 Million ≈ $4.96 Million |
+153.66% |
| 2018-12-31 | Skr18.16 Million ≈ $1.95 Million |
-62.30% |
| 2017-12-31 | Skr48.18 Million ≈ $5.18 Million |
+38.66% |
| 2016-12-31 | Skr34.75 Million ≈ $3.74 Million |
+157.14% |
| 2015-12-31 | Skr13.51 Million ≈ $1.45 Million |
+47.51% |
| 2014-12-31 | Skr9.16 Million ≈ $985.78K |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more